Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Subscribe To Our Newsletter & Stay Updated
